“…This pathway is key to the biotransformation of imipramine, clozapine, olanzapine, tacrine, methadone, caffeine, cyclobenzaprine, haloperidol, and theophylline (Table 2). Fluvoxamine is a potent inhibitor of CYP 1A2 activity [Brosen et al, 1993], and interactions with 1A2 substrates are well documented [Xu et al, 1996;Kuo et al, 1998;Spigset, 1998;Alderman and Frith, 1999;Larsen et al, 1999] The addition of fluvoxamine to steady-state clozapine therapy has caused 5-to 10-fold increases in clozapine plasma concentration [Heeringa et al, 1999] . In our own experience, this interaction can be very potent.…”